Sarepta therapeutics announces global licensing and collaboration agreement with arrowhead pharmaceuticals for multiple clinical and preclinical sirna programs

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with arrowhead pharmaceuticals, inc. (nasdaq: arwr). sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (cns), and the lungs. the agreement will add meaningfully to s.
SRPT Ratings Summary
SRPT Quant Ranking